Zyrop 4000 Injection contains Recombinant Human Erythropoietin Alfa (4000 IU), a glycoprotein hormone that stimulates erythropoiesis, the production of red blood cells, by acting on erythroid progenitor cells in the bone marrow. It is primarily indicated for the treatment of anemia associated with chronic kidney disease (CKD), including patients on dialysis and those not on dialysis. Zyrop 4000 is also utilized to manage anemia in patients undergoing chemotherapy for non-myeloid malignancies, reducing the need for blood transfusions. Additionally, it may be prescribed for anemia related to zidovudine therapy in HIV-infected patients and to reduce transfusion requirements in elective, non-cardiac, non-vascular surgery. The dosage and administration should be individualized based on the patient’s hemoglobin levels, clinical response, and underlying condition, with careful monitoring to avoid excessive erythropoiesis and associated risks such as hypertension and thromboembolic events. Zyrop 4000 Injection is administered via subcutaneous or intravenous routes under strict aseptic conditions. Contraindications include uncontrolled hypertension and hypersensitivity to erythropoietin or any component of the formulation. Regular monitoring of hemoglobin, hematocrit, and blood pressure is essential during therapy to ensure safety and efficacy.